Prof. Junqiang Chen 陈俊强
Chief Physician, Professor
Department of Radiation Oncology, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis, radiotherapy, chemotherapy, immunotherapy, and comprehensive treatment for esophageal cancer, lung cancer, mediastinal tumors, skin cancer, and bone and soft tissue tumors.
Dr. Chen graduated from Nanjing Railway Medical College in 1989. A Professor and Chief Physician at Fujian Cancer Hospital, Dr. Chen trained at Fudan University Shanghai Cancer Center in 1997 and was a visiting scholar at MD Anderson Cancer Center in 2009. Dr. Chen focuses on clinical practice, teaching, and research in radiation oncology, with extensive experience in esophageal cancer.
Professional roles
- Member, Esophageal Cancer Group, Radiation Oncology Branch, Chinese Medical Association
- Vice Chair, Tumor Rehabilitation Branch, Chinese Society of Gerontology and Geriatrics
- Standing Committee Member, Minimally Invasive Comprehensive Treatment of Craniocerebral Diseases Branch, China Anti-Cancer Association
- Chair, Fujian Provincial Committee on Tumor Rehabilitation, Fujian Anti-Cancer Association
Name order: in Chinese the family name comes first (Chen Junqiang). Papers usually list the name as Junqiang Chen or Chen J.
Selected publications
70 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Radiother Oncol, 2026 (first author): Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial. PubMed 41412437
- J Med Chem, 2026 (senior author): Sequential FAP and Mitochondria-Targeting Radioconjugate with High Tumor Uptake Efficiency and Long Retention Time for Radiopharmaceutical Therapy. PubMed 41849695
- Mol Pharm, 2026 (senior author): Endoplasmic Reticulum Mediates Prolonged Tumor Retention of FAPI Radioconjugates and Enhanced Radiotherapeutic Efficacy. PubMed 41813582
- Mater Today Bio, 2026 (senior author): A precise theranostic nanoplatform amplifies anti-tumor efficacy via copper ionophores and sonodynamic therapy. PubMed 41800456
- Radiat Oncol, 2025 (senior author): Validation and refinement of the 8th edition of the AJCC staging system for esophageal squamous cell carcinoma treated with definitive IMRT or chemo-IMRT: a Chinese multi-institutional retrospective study. PubMed 41225591
- BMC Cancer, 2025 (senior author): Development of a prognostic nomogram and risk stratification system for elderly patients with esophageal squamous cell carcinoma undergoing definitive radiotherapy: a multicenter retrospective analysis (3JECROG R-03 A). PubMed 39780142
- Cancer Manag Res, 2019 (senior author): Primary tumor regression patterns in esophageal squamous cell cancer treated with definitive chemoradiotherapy and implications for surveillance schemes. PubMed 31114372
- Front Genet, 2018 (senior author): Long Noncoding RNA FAM201A Mediates the Radiosensitivity of Esophageal Squamous Cell Cancer by Regulating ATM and mTOR Expression via miR-101. PubMed 30574162
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion